Mineralys Therapeutics (MLYS) Equity Average (2022 - 2026)

Mineralys Therapeutics has disclosed Equity Average across 5 years of filings, most recently posting $642.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at $642.4 million, up 141.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $642.4 million (up 141.14% YoY), and the FY2025 annual result was $419.0 million, up 93.79% from the prior year.
• Equity Average came in at $642.4 million for Q1 2026 at Mineralys Therapeutics, up from $611.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $642.4 million in Q1 2026 to a low of -$47.8 million in Q4 2022.
• The 5-year median for Equity Average is $270.5 million (2023), against an average of $261.4 million.
• Across the five-year window, Equity Average surged 961.81% in 2023 and declined 15.24% in 2024, its largest moves.
• Mineralys Therapeutics' Equity Average stood at -$47.8 million in 2022, then soared by 627.96% to $252.6 million in 2023, then slipped by 15.24% to $214.1 million in 2024, then jumped by 185.65% to $611.6 million in 2025, then gained by 5.05% to $642.4 million in 2026.
• The last three Equity Average figures came in at $642.4 million (Q1 2026), $611.6 million (Q4 2025), and $445.0 million (Q3 2025), per Business Quant data.